Popular Articles

Afinitor(R) Phase II Data Show Positive Results For Patients With Multiple Types Of Lymphoma, Leading To Phase III Trial
New data show that Afinitor(R) (everolimus) tablets significantly shrunk tumors in 33% of patients with relapsed non-Hodgkin"s lymphoma (NHL) and Hodgkin"s disease(1). Based on results from this study and other early-stage research, Novartis has initiated a Phase III trial in the most common NHL, diffuse large B-cell lymphoma (DLBCL).
generic viagra online
Psychiatrists Begin Revising Diagnostic Manual For Mental Illnesses
Over the next 18 months, psychiatrists will revise the American Psychiatric Association"s Diagnostic and Statistical Manual of Mental Disorders, which is used to determine how U.S. residents" mental health is assessed, diagnosed and treated, the Los Angeles Times reports. Since the manual was last updated in 1994, technologies such as brain imaging and new understandings of the biological and genetic causes of many disorders have "almost guaranteed alterations" in the number of mental disorders included in fifth DSM volume, which is scheduled to be published in 2012, the Times reports.While some psychiatrists argue the manual should be broad enough to determine treatment for those who need it, others are concerned that if too broad, the manual will diagnose conditions that would otherwise be considered normal human behavior. David Kupfer, a psychiatrist at the University of Pittsburgh"s Western Psychiatric Institute and Clinics and chair of the DSM-V task force, said the DSM-V will recognize variations of disorders that have not been seen as part of "classic" illnesses, and will describe disorders in more detail, including how they differ based on race, gender, age, physical health and culture. Health insurance companies use the manual to determine coverage options for certain treatments.People involved in the revisions said the manual will be a better reflection of mental conditions of "real" people, rather than just those with the most severe cases of disorders or obvious diagnoses, the Times reports (Roan, Los Angeles Times, 5/26).
News of the day
Novel Vaccine Approach Offers Hope In Fight Against HIV
A research team may have broken the stubborn impasse that has frustrated the invention of an effective HIV vaccine, by using an approach that bypasses the usual path followed by vaccine developers. By using gene transfer technology that produces molecules that block infection, the scientists protected monkeys from infection by a virus closely related to HIV -- the simian immunodeficiency virus, or SIV -- that causes AIDS in rhesus monkeys.
Health Insurance

Scrap England's "Shameful" Prescription Charge, Urges DTB

The prescription charge in England is a tax in all but name - and an unfair one at that - and should be axed, says Drug and Therapeutics Bulletin (DTB). England is the only one of the four UK countries that has either not already scrapped the charge or plans to do so by April 2011. DTB argues that, contrary to popular belief, the ÷£7.20 currently levied on prescription medicines does not directly reflect the cost of the drug prescribed and does not specifically fund health services. Instead, the charge is for raising general tax revenue, it says. With the abolition of the charge in Scotland, Wales, and Northern Ireland, a key argument put forward for its retention - namely that it reminds people of the cost of medicines, and acts as a deterrent to overuse prescription services - rings hollow, says DTB. "Why only people in England need such a reminder is far from clear," it says. Those who support the charge argue that many people are exempt. But these exemptions are totally illogical, says DTB. And they are so confusing that even NHS Prescription Services is setting up an online quiz for healthcare professionals to test their knowledge about whom they should and should not be charging. The other concern that advocates for the retention of the charge advance is that its abolition might prompt patients to demand medicines "of dubious value." The counter argument is that if these products are so questionable, they should not be available for prescription in the first place, insists DTB. Having demolished the arguments in support of keeping the prescription charge in England, DTB concludes: "[It] is a poorly conceived, manifestly unfair tax that shames the NHS and the Department of Health. It needs to go." Drug And Therapeutics Bulletin


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):